Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 + Adebrelimab in Perioperative Treatment of MIBC
NCT06879145Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102 in muscle-invasive bladder cancer (MIBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Apr 2025; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06879145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879145.